- Open
- 0.09
- High
- 0.10
- Low
- 0.07
- Close
- 0.08
- Change
- -0.01 (-16.67%)
- Volume
- 17,725,892
| 5 Nov 2026 | 07:00:02 | US Patent Office allows ketamine patent |
| 30 Oct 2026 | 07:00:04 | Directorate change |
| 16 Oct 2026 | 11:18:29 | Holding(s) in Company |
| 13 Oct 2026 | 07:00:02 | MOU Reached with ICAD |
| 1 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 May 2026 | Annual Report for the year ended 31 December 2025 | |
| 7 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Solvonis Therapeutics PLC is a biopharmaceutical company focused on developing small-molecule therapeutics for central nervous system (CNS) disorders, particularly in the areas of addiction and psychiatry. The company has a pipeline that includes two programs for Alcohol Use Disorder (AUD): SVN-001, targeting severe AUD in the UK and EU, and SVN-002, aimed at moderate-to-severe AUD in the U.S. and other markets. Solvonis operates through a model that combines later-stage clinical assets with discovery-stage innovation, primarily in the UK and U.S. markets.
| 5 Nov 2026 | 07:00:02 | US Patent Office allows ketamine patent |
| 30 Oct 2026 | 07:00:04 | Directorate change |
| 16 Oct 2026 | 11:18:29 | Holding(s) in Company |
| 13 Oct 2026 | 07:00:02 | MOU Reached with ICAD |
| 1 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 May 2026 | Annual Report for the year ended 31 December 2025 | |
| 7 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Solvonis Therapeutics PLC is a biopharmaceutical company focused on developing small-molecule therapeutics for central nervous system (CNS) disorders, particularly in the areas of addiction and psychiatry. The company has a pipeline that includes two programs for Alcohol Use Disorder (AUD): SVN-001, targeting severe AUD in the UK and EU, and SVN-002, aimed at moderate-to-severe AUD in the U.S. and other markets. Solvonis operates through a model that combines later-stage clinical assets with discovery-stage innovation, primarily in the UK and U.S. markets.
| 6 Oct 2026 |
| 07:00:03 |
| Investor Webinar – 15 October 2026 |
| 25 Aug 2026 |
| Solvonis raises £1.3m to fund three clinical programmes |
| 6 Aug 2026 | US drug agency to fund further testing of Solvonis addiction candidate |
| 6 Aug 2026 | US drug agency to fund further testing of Solvonis addiction candidate - UPDATE |
| 13 Jul 2026 | US Research house initiates Solvonis coverage citing differentiated addiction strategy |
| 27 Jun 2026 | Solvonis Therapeutics, Tertiary Minerals, CelLBxHealth, Coinsilium, Eco Buildings, Frontier IP |
| 27 Jun 2026 | Solvonis CEO on progress with potential alcohol use disorder treatment - ICYMI |
| 6 Oct 2026 |
| 07:00:03 |
| Investor Webinar – 15 October 2026 |
| 25 Aug 2026 |
| Solvonis raises £1.3m to fund three clinical programmes |
| 6 Aug 2026 | US drug agency to fund further testing of Solvonis addiction candidate |
| 6 Aug 2026 | US drug agency to fund further testing of Solvonis addiction candidate - UPDATE |
| 13 Jul 2026 | US Research house initiates Solvonis coverage citing differentiated addiction strategy |
| 27 Jun 2026 | Solvonis Therapeutics, Tertiary Minerals, CelLBxHealth, Coinsilium, Eco Buildings, Frontier IP |
| 27 Jun 2026 | Solvonis CEO on progress with potential alcohol use disorder treatment - ICYMI |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £32m | -0.2% | |
| £10m | -0.1% | |
SVNSSolvonis Therapeutics PLC | £6m | -0.7% |
| £4m | -0.2% | |
| £3m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £32m | -0.2% | |
| £10m | -0.1% | |
SVNSSolvonis Therapeutics PLC | £6m | -0.7% |
| £4m | -0.2% | |
| £3m | -0.8% |